News & Events
- Technology Networks: Advances in Drug Discovery & Development 2025
- Evaluating Ai-driven Design and Discovery Tools in RNA Therapeutics
- 'Turning Science into Business' AI & ML summit: Navigating AI-driven drug discovery
- Transforming Target and Drug Discovery with Visual Biology derived AI Disease Models
- Visual biology AI neural network recognize disease signatures in cellular pathway visualizations
- Leveraging large-scale mRNA biology data to advance disease understanding
- mRNA Is Never Naked: Exploring RBP Target Space & Therapeutic Opportunities
- Technologies developed to study mRNA life cycle
- Exposing hidden targets within the mRNA regulation space
-
4th Annual RNA-Targeting Small Molecule Drugs hosted by CHI as part of the 18th Annual Drug Discovery Event
When:
Where: San Diego, CA & VirtualAnima Biotech has been invited to give a presentation during the 18th Annual Drug Discovery Chemistry as part of the RNA-Targeting Small Molecule Drugs track of the Conference held from April 10th to April 13th, 2023 in San Diego, CA and virtually. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Discovery of Small Molecule mRNA Modulators Using Phenotypic Screening with AI-Driven MoA Elucidation” on Tuesday, April 11, 2023 from 8:10 – 8:40 AM PDT.
-
American Chemical Society Spring Meeting (ACS 2023)
When:
Where: Indianapolis, IN & HybridAnima Biotech has been invited to give a presentation during the ACS Spring 2023 Meeting held in Indianapolis, IN and virtually. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will present a talk titled “mRNA translation regulation: Novel targets in drug discovery,” during the “Lost in Translation? Targeting Protein Synthesis as a Therapeutic Strategy” session. Dr. Alroy’s oral presentation takes place on Monday, March 27, 2023 at 4:00 p.m. ET.
-
LSX RNA Leaders Europe Congress
When:
Where: Basel, SwitzerlandAnima Biotech has been invited to give a presentation at the RNA Leaders Congress in Basel Switzerland. Our head of early discovery, Yoni Sheinberger, Ph.D., will give a talk titled, “mRNA Lighting platform | Discovery of mRNA biology modulators and their mechanisms of action” on Mar. 15th at 5:00 PM CET during the “Targeting RNA with Small Molecules” session. Dr. Sheinberger will discuss our proprietary mRNA Lightning platform and how Anima is identifying active compounds and their mechanisms of action.
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
When:
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
“This collaboration will give AbbVie access to Anima’s leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering and developing drugs to make a difference in patient’s lives,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. “Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets with implications across multiple therapy areas.”
”Anima’s differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline,” said Yochi Slonim, co-founder and chief executive officer, Anima. “We are excited to partner with AbbVie, a recognized global leader in Oncology and Immunology, and are looking forward to start working with their excellent scientific team in a close collaboration.”Under the terms of the agreement, Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration.
-
Biotech Showcase 2023
When:
Where: San Francisco, CAAnima Biotech will be attending this year’s Biotech Showcase and is looking forward to connecting with other industry experts. Our chief business officer, Kevin Pong, Ph.D., will give a corporate presentation on Jan. 9th at 9:45 A.M. PST highlighting our unique approach to the discovery of small molecule mRNA drugs.
-
5th RNA Targeting Drug Development Summit
When:
Where: Boston, MAAnima Biotech has been invited to participate in a panel discussion and presentation at the 5th RNA Targeting Drug Development Summit. Our chief business officer, Kevin Pong, Ph.D., will participate in the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecule on Dec. 14th at 11:50 A.M. Additionally, he will give a talk titled, “mRNA Lightning Platform-Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action” on Dec. 15th at 11:45 A.M. Dr. Pong will highlight our mRNA Lightning platform and how our unique AI driven MOA elucidation and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology.
-
4th NovAliX Virtual Conference
When:
Where: DigitalAnima Biotech has been invited to participate in a short session at the 4th NovAliX Virtual Conference. Our co-founder and chief scientific officer, Iris Alroy, Ph.D., will present a short talk titled “Discovery of Small Molecule mRNA Drugs and their Mechanisms of Action using Phenotypic Screening with AI-driven MOA Elucidation” taking place from 11:00 AM to 1:00 PM ET. The talk highlights our mRNA Lightning platform and how our unique AI and phenotypic screening-based approach has elucidated novel targets that affect mRNA biology, driving our lead programs in fibrosis and oncology with demonstrated efficacy in animal and patient-derived models.
-
4th Annual Targeting RNA
When:
Where: Boston, MAAnima Biotech has been invited to participate at the 4th Annual Targeting RNA conference hosted by Cambridge Healthtech Institute. Kevin Pong, Ph.D., Anima’s Chief Business Officer, will give a presentation titled, “Discovery of Small Molecule mRNA Drugs and Their Mechanisms of Action Using Phenotypic Screening with AI-Driven MOA Elucidation” taking place on October 18th at 10:25 a.m. ET.
-
IPF Summit 2022
When:
Where: Boston, MAAnima Biotech has been invited to participate in the IPF Summit 2022 hosted by Hanson Wade.
Moty Klepfish, Ph.D., Anima’s Principal Scientist, Fibrosis will give a presentation titled, “Discussing Collagen Type I mRNA Translation Inhibition in Idiopathic Pulmonary Fibrosis,” taking place on August 30th at 2:30 p.m. ET.
The IPF Summit is the largest gathering of IPF experts spanning four days of topics such as rethinking senescence to effectively repairing and regenerating lung tissue, to leveraging synthetic control arms in placebo-controlled trials.
-
Anima Biotech achieves milestone in Takeda collaboration
When:
Anima Biotech announced that the company has achieved a milestone in its collaboration with Takeda.
The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.
Anima Biotech and Takeda entered in the collaboration in March 2021 to discover and develop a new class of medicines for genetically-defined neurological diseases. Under the terms of the agreement, Anima Biotech used its mRNA Lightning platform to discover novel mRNA translation modulators against the collaboration targets. The collaboration also includes Anima’s Huntington’s Disease program against the HTT mutated protein.